BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prevots DR. Completeness of Reporting for Paralytic Poliomyelitis, United States, 1980 Through 1991: Implications for Estimating the Risk of Vaccine-Associated Disease. Arch Pediatr Adolesc Med 1994;148:479. [DOI: 10.1001/archpedi.1994.02170050037007] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus Vaccine–Live. Plotkin's Vaccines. Elsevier; 2018. pp. 866-917.e16. [DOI: 10.1016/b978-0-323-35761-6.00048-1] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
2 Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SGF, Cochi SL, Thompson KM. Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine-Related Polioviruses: Poliovirus Transmission and Evolution Model. Risk Analysis 2013;33:703-49. [DOI: 10.1111/risa.12044] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 9.4] [Reference Citation Analysis]
3 Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations. An epidemiological review. Paediatr Drugs 2000;2:273-90. [PMID: 10946416 DOI: 10.2165/00128072-200002040-00004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
4 Yee PTI, Tan SH, Ong KC, Tan KO, Wong KT, Hassan SS, Poh CL. Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice. Sci Rep 2019;9:4805. [PMID: 30886246 DOI: 10.1038/s41598-019-41285-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
5 Fescharek R, Budde RK, Arras C. OPV vs IPV--could placental immunity reduce the number of vaccine-associated paralytic poliomyelitis? Vaccine 1997;15:1707-8. [PMID: 9364670 DOI: 10.1016/s0264-410x(97)85581-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Weibel RE, Benor DE. Reporting vaccine-associated paralytic poliomyelitis: concordance between the CDC and the National Vaccine Injury Compensation Program. Am J Public Health 1996;86:734-7. [PMID: 8629730 DOI: 10.2105/ajph.86.5.734] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
7 Modlin JF. Poliomyelitis and Poliovirus Immunization. In: Rotbart HA, editor. Human Enterovirus Infections. Washington: ASM Press; 1995. pp. 193-220. [DOI: 10.1128/9781555818326.ch9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
8 Alirezaie B, Taqavian M, Aghaiypour K, Esna-Ashari F, Shafyi A. Phenotypic and genomic analysis of serotype 3 Sabin poliovirus vaccine produced in MRC-5 cell substrate. J Med Virol 2011;83:897-903. [PMID: 21412797 DOI: 10.1002/jmv.21804] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Halsey NA, Edwards KM, Dekker CL, Klein NP, Baxter R, Larussa P, Marchant C, Slade B, Vellozzi C; Causality Working Group of the Clinical Immunization Safety Assessment network. Algorithm to assess causality after individual adverse events following immunizations. Vaccine 2012;30:5791-8. [PMID: 22507656 DOI: 10.1016/j.vaccine.2012.04.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
10 Lambo JA, Nagulesapillai T. Neonatal tetanus elimination in Pakistan: progress and challenges. Int J Infect Dis 2012;16:e833-42. [PMID: 22940280 DOI: 10.1016/j.ijid.2012.07.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
11 de Oliveira LH, Struchiner CJ. Vaccine-associated paralytic poliomyelitis: a retrospective cohort study of acute flaccid paralyses in Brazil. International Journal of Epidemiology 2000;29:757-63. [DOI: 10.1093/ije/29.4.757] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf 2016;25:215-22. [PMID: 26602179 DOI: 10.1002/pds.3918] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
13 Yuki Y, Kiyono H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines 2009;8:1083-97. [PMID: 19627189 DOI: 10.1586/erv.09.61] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
14 Baicus A. History of polio vaccination. World J Virol 2012;1:108-14. [PMID: 24175215 DOI: 10.5501/wjv.v1.i4.108] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
15 Sutter RW, Prevots DR, Cochi SL. Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States. Pediatr Clin North Am 2000;47:287-308. [PMID: 10761505 DOI: 10.1016/s0031-3955(05)70208-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Prevots DR, Strebel PM. Poliomyelitis Prevention in the United States: New Recommendations for Routine Childhood Vaccination Place Greater Reliance on Inactivated Poliovirus Vaccine. Pediatr Ann 1997;26:378-83. [DOI: 10.3928/0090-4481-19970601-09] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
17 Hazell L, Shakir SAW. Under-Reporting of Adverse Drug Reactions: A Systematic Review. Drug Safety 2006;29:385-96. [DOI: 10.2165/00002018-200629050-00003] [Cited by in Crossref: 851] [Cited by in F6Publishing: 606] [Article Influence: 56.7] [Reference Citation Analysis]
18 Mallet L, Pelloquin F, Brigaud M, Caudrelier P, Bandet R, Xueref C, Fuchs F, Gibelin N, Goldman C, Moulin JC, de Fraipont F, Montagnon B, Peyron L, Aymard M. Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on vero cells or on primary monkey kidney cells. J Med Virol 1997;52:50-60. [DOI: 10.1002/(sici)1096-9071(199705)52:1<50::aid-jmv9>3.0.co;2-q] [Cited by in Crossref: 12] [Article Influence: 0.5] [Reference Citation Analysis]
19 Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. Vaccines. Elsevier; 2008. pp. 631-85. [DOI: 10.1016/b978-1-4160-3611-1.50030-1] [Cited by in Crossref: 24] [Article Influence: 1.8] [Reference Citation Analysis]
20 Zangwill KM, Yeh SH, Wong EJ, Marcy SM, Eriksen E, Huff KR, Lee M, Lewis EM, Black SB, Ward JI. Paralytic Syndromes in Children: Epidemiology and Relationship to Vaccination. Pediatric Neurology 2010;42:206-12. [DOI: 10.1016/j.pediatrneurol.2009.10.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
21 Foiadelli T, Savasta S, Battistone A, Kota M, Passera C, Fiore S, Bino S, Amato C, Lozza A, Marseglia GL, Fiore L. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis.BMC Infect Dis. 2016;16:277. [PMID: 27287521 DOI: 10.1186/s12879-016-1587-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
22 Halsey NA, Blatter M, Bader G, Thoms ML, Willingham FF, O'donovan JC, Pakula L, Berut F, Reisinger KS, Meschievitz C. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine: . The Pediatric Infectious Disease Journal 1997;16:675-9. [DOI: 10.1097/00006454-199707000-00010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
23 Amanna IJ, Slifka MK. Successful Vaccines. Curr Top Microbiol Immunol 2020;428:1-30. [PMID: 30046984 DOI: 10.1007/82_2018_102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
24 Klevens R, Fleming PL, Li J, Gaines C, Gallagher K, Schwarcz S, Karon JM, Ward JW. The Completeness, Validity, and Timeliness of AIDS Surveillance Data. Annals of Epidemiology 2001;11:443-9. [DOI: 10.1016/s1047-2797(01)00256-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
25 Finn A, Bell F. Polio vaccine: is it time for a change? Arch Dis Child 1998;78:571-3; discussion 573-4. [PMID: 9713019 DOI: 10.1136/adc.78.6.571] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
26 Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, Cetron MS; GeoSentinel Yellow Fever Working Group. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001;7:945-51. [PMID: 11747720 DOI: 10.3201/eid0706.010605] [Cited by in Crossref: 102] [Cited by in F6Publishing: 78] [Article Influence: 5.4] [Reference Citation Analysis]
27 Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf 2017;16:761-7. [PMID: 28447485 DOI: 10.1080/14740338.2017.1323867] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
28 Gäwert L, Hierse F, Zink A, Strangfeld A. [The importance of patient perspective in drug surveillance systems]. Z Rheumatol 2010;69:795-802. [PMID: 21063828 DOI: 10.1007/s00393-010-0642-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Ravanfar P, Satyaprakash A, Creed R, Mendoza N. Existing antiviral vaccines. Dermatologic Therapy 2009;22:110-28. [DOI: 10.1111/j.1529-8019.2009.01224.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
30 Jallow S, Wilmshurst JM, Howard W, Copelyn J, Seakamela L, Chan KW, Sebunya R, Sibiya R, Du Plessis H, Jacobs C, Berkowitz N, Blumberg L, McCarthy K, Maseti E, Kamupira M, Dlamini N, Gumede N, Diop OM, Lau YL, Moonsamy S, Eley B, Suchard M. Accelerated Immunodeficiency-associated Vaccine-derived Poliovirus Serotype 3 Sequence Evolution Rate in an 11-week-old Boy With X-linked Agammaglobulinemia and Perinatal Human Immunodeficiency Virus Exposure. Clin Infect Dis 2020;70:132-5. [PMID: 31086993 DOI: 10.1093/cid/ciz361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Amanna IJ, Slifka MK. Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Rev Vaccines 2016;15:1519-33. [PMID: 27267203 DOI: 10.1080/14760584.2016.1198259] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
32 Liu Q, Jia J, Yang T, Fan Q, Wang L, Ma G. Pathogen-Mimicking Polymeric Nanoparticles based on Dopamine Polymerization as Vaccines Adjuvants Induce Robust Humoral and Cellular Immune Responses. Small 2016;12:1744-57. [PMID: 26849717 DOI: 10.1002/smll.201503662] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
33 Edwards EA, Grant CC, Huang QS, Powell KF, Croxson MC. A case of vaccine-associated paralytic poliomyelitis. J Paediatr Child Health 2000;36:408-11. [PMID: 10940185 DOI: 10.1046/j.1440-1754.2000.00514.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Tebbens RJD, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM. Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication. Risk Analysis 2006;26:1471-505. [DOI: 10.1111/j.1539-6924.2006.00827.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 100] [Article Influence: 8.0] [Reference Citation Analysis]
35 D'souza RM, Watson C, Kennett M. Australia's contribution to global polio eradication initiatives. Australian and New Zealand Journal of Public Health 1999;23:289-94. [DOI: 10.1111/j.1467-842x.1999.tb01258.x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
36 Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. Vaccination against polio should not be stopped. Nat Rev Microbiol 2007;5:952-8. [PMID: 17965726 DOI: 10.1038/nrmicro1769] [Cited by in Crossref: 60] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
37 Viret J, Dietrich G, Favre D. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Vaccine 2004;22:2457-69. [DOI: 10.1016/j.vaccine.2003.12.033] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
38 Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal 2006;26:1423-40. [PMID: 17184390 DOI: 10.1111/j.1539-6924.2006.00831.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
39 Guillot S, Caro V, Cuervo N, Korotkova E, Combiescu M, Persu A, Aubert-Combiescu A, Delpeyroux F, Crainic R. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J Virol 2000;74:8434-43. [PMID: 10954543 DOI: 10.1128/jvi.74.18.8434-8443.2000] [Cited by in Crossref: 154] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
40 Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996;14:735-46. [DOI: 10.1016/0264-410x(95)00211-i] [Cited by in Crossref: 79] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
41 Horie H, Yoshida H, Matsuura K, Miyazawa M, Wakabayashi K, Nomoto A, Hashizume S. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J Med Virol 2002;68:445-51. [DOI: 10.1002/jmv.10224] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
42 Hinman AR, Gindler J, Tinker S, Markowitz L, Atkinson W, Dales L, Papania M. Acute Measles Mortality in the United States, 1987–2002. The Journal of Infectious Diseases 2004;189:S69-77. [DOI: 10.1086/378565] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
43 Rivest P, Sagot B, Bédard L. Evaluation of the completeness of reporting of invasive meningococcal disease. Can J Public Health 1999;90:250-2. [PMID: 10489722 [PMID: 10489722 DOI: 10.1007/bf03404126] [Cited by in Crossref: 10] [Article Influence: 0.5] [Reference Citation Analysis]
44 Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine—live. Vaccines. Elsevier; 2013. pp. 598-645. [DOI: 10.1016/b978-1-4557-0090-5.00035-5] [Cited by in Crossref: 36] [Article Influence: 4.5] [Reference Citation Analysis]